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Introduction
Throughout the past couple of decades, dyslipidemia in pediatrics has been a subject of
growing concern due to its correlation with both obesity and cardiovascular risk factors.
Research has shown that if dyslipidemia goes untreated throughout childhood, a child is at an
increased risk of developing early atherosclerosis, cardiovascular disease, heart attacks, and
stroke during adulthood (DeFerranti & Newburger, 2017). The American Academy of Pediatrics
has clinical practice guidelines in place for healthcare providers that outlines when a child should
undergo dyslipidemia screening. The hope is that through early detection and treatment, a child’s
morbidity and mortality from cardiovascular disease will be drastically improved down the road.
There has been a lack of research that examines why dyslipidemia screening rates are
historically low throughout the pediatric primary care population and what needs to be done to
address this. It is important that healthcare providers are provided with both education and
evidence-based research that demonstrates the need behind dyslipidemia screening in childhood.
The aim of this study is to provide education to healthcare providers at a pediatric primary care
clinic to increase screening rates and provide children with the best possible preventive care that
they deserve.
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Abstract
PURPOSE: The purpose of this study is to examine the outcome of healthcare provider
education on the incidence of dyslipidemia screening in a pediatric primary care clinic.
METHODS: The design of this study was a descriptive pre and post design to evaluate if
dyslipidemia screening rates, knowledge, and self-efficacy of healthcare providers changed
following an education series at a general pediatric clinic in Lexington, KY. The rates of
dyslipidemia screening were calculated prior to providing provider education as well as
afterwards to see whether there was an improvement in screening rates. Provider’s knowledge
and confidence before the education series was also assessed via a survey. The sample of this
study consisted of 11 pediatric healthcare providers at a general pediatric clinic. The secondary
sample of this study were the medical records of children between the ages of 9 and 11 years
who presented to a general pediatric clinic for an annual well-child exam. The sample consisted
of 256 medical records during the pre-education time period, June 2018 to August 2018, and 65
medical records during the post-education time period, September 10, 2018 to October 19, 2018.
RESULTS: The Chi-square test of association was used to compare dyslipidemia screening rates
before and after the educational intervention was given in the pediatric primary care clinic. The
Chi-square test was also used after the educational burst e-mail was sent to all healthcare
providers three weeks after the start of the study. Three months prior to the educational
intervention being implemented, 17.2% of providers performed routine dyslipidemia screening
on children between the ages of 9-11 years during annual well-child exams. Post-educational
intervention, dyslipidemia screening rates increased to 24.6% (P=0.1701). An e-mail serving as
an educational burst was sent to all providers at the clinic three weeks after the start of the study,
regardless of whether they received education, reminding them of the evidence-based guidelines
2

and the need to screen. Dyslipidemia screening rates increased from 18.75% prior to the e-mail
to 26.53% after the e-mail was sent (P=0.7409). Lastly, descriptive statistics including means
and standard deviations were used to summarize healthcare provider’s confidence and
knowledge in dyslipidemia screening. The results yielded that many healthcare providers do not
feel confident in the evidence-based guidelines regarding dyslipidemia screening and
management in the pediatric primary care population nor feel comfortable treating.
CONCLUSION: Dyslipidemia screening rates improved from 17.2% to 24.6%, an increase of
43% between the two percentages, at a general pediatric clinic after the educational intervention
was implemented. This is a significant improvement and evidence that education on the current
AAP guidelines was needed. Of the providers that participated, 81.8% strongly agreed that they
felt more confident in when and how to screen, diagnose, and manage dyslipidemia in children
between the ages of 9 and 11 years after they received education. Providing quality, evidencebased care is of utmost importance in the clinic. This intervention will likely lead to improved
early diagnoses and treatment of dyslipidemia in the pediatric population and reduce morbidity
and mortality in adulthood.
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Background
Dyslipidemia is a known risk factor for cardiovascular disease (CVD) that often
manifests during childhood and adolescence (De Ferranti & Newburger, 2017). Heart disease is
the leading cause of death for both men and women, contributing to 630,000 deaths each year
(Cholesterol, 2017). Twenty percent of children in the United States between the ages of 6 and
19 years have adverse levels of one or more lipid value (De Ferranti & Newburger, 2017). The
majority of lipid disorders exhibit no signs or symptoms. Therefore, it is crucial that screening be
conducted on every child regardless of whether there are known risk factors or a family history.
It is estimated that 50 percent of children with abnormal serum lipoprotein values will continue
to have elevated lipid levels into adulthood (De Ferranti & Newburger, 2017). The American
Academy of Pediatrics (AAP) in conjunction with the National Heart Lung and Blood Institute
(NHLBI) Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction
in Children and Adolescents endorse that all children between the ages of 9 and 11 years undergo
dyslipidemia screening before the onset of puberty. Members of the AAP in Utah were surveyed
by the National Institute of Health in 2011 to assess if they were performing routine dyslipidemia
screenings on all children seen in clinic between the ages of 9 and 11. Of the 118 respondents
who practiced primary care, only 15% screened all children at well-child checks (Stipelman et.
al., 2016). In an evidence report and systematic literature review published by the Journal of the
American Medical Association (JAMA) in 2016, it was found that current rates of dyslipidemia
screening in children and adolescents are low, estimated between 2.5% and 3.2% (Lozano et. al,
2016). These statistics are staggering and a direct indication that this problem in the pediatric
population needs to be addressed. Through early identification of dyslipidemia, a child’s lipid
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profile can be improved through lifestyle modifications or medication which reduces their risk of
developing premature atherosclerosis and CVD in the future (De Ferranti & Newburger, 2017).
The history of dyslipidemia has been traditionally centered on Familial Heterozygous
Hypercholesterolemia (FH) which is an inherited, autosomal dominant condition that occurs in 1
in every 500 individuals (Cook et. al, 2011). However, with childhood obesity rates tripling over
the past 30 years, there is now a heightened concern for a second and larger population of
children with dyslipidemia secondary to obesity (Cook et. al., 2011). Pediatric dyslipidemia
primarily effects children who are overweight (BMI 85th to 95th percentile) and obese (BMI
>95th percentile) (De Ferranti & Newburger, 2017). In an analysis of National Health and
Nutrition Examination Survey (NHAMES), it was found that 14% of youths who were normal
weight, 22% of youths who were overweight, and 43% of youths who were obese had adverse
lipid levels (De Ferranti & Newburger, 2017). It is estimated that 100,000 children under the age
of 17 and 400,000 adolescents between the ages of 17 and 21 would qualify for statin therapy in
the United States based on the current NHBLI and AAP recommendations (De Ferranti &
Newburger, 2017).
Dyslipidemia in children is characterized by disorders of lipoprotein metabolism that
result in the following abnormalities: high total cholesterol, high low-density lipoprotein
cholesterol, high non-high-density lipoprotein cholesterol, high triglycerides, and low highdensity lipoprotein cholesterol (De Ferranti & Newburger, 2017). Normal lipid values in children
vary by age and sex. In addition to variance, these values change with normal growth and
maturation. Therefore, it is critical that screening be done at specific intervals to avoid false
negatives or positives. Normal lipid and lipoprotein values are measurable and come from a
collaboration of data collected by the Lipid Research Clinical (LRC) Prevalence Study and from
5

the United States National Health and Nutrition Examination Surveys (De Ferranti &
Newburger, 2017).
Public health efforts are now being made to reduce cardiovascular risk factors, such as
pediatric dyslipidemia, to reduce the overall morbidity and mortality rate of cardiovascular
disease in the future (Cook et. al., 2011). The World Health Organization reported that there
were 5.7 million deaths to stroke in 2005 and speculates that this number may reach 23 million
by 2030 (Kuklina et. al., 2012). According to the CDC, heart disease contributes to 630,000
deaths each year (Cholesterol, 2017). Early recognition and treatment of pediatric dyslipidemia
could play a significant part in decreasing the mortality rate of such conditions.
Purpose
The purpose of this study was to examine the outcome of healthcare provider education
on the incidence of dyslipidemia screening at a general pediatric clinic in Lexington, KY. The
rates of dyslipidemia screening were examined prior to providing education to healthcare
providers as well as afterwards through a descriptive pre and post design. Provider’s knowledge
and confidence before the education series was obtained through an anonymous survey. The
overall goal of this project was to increase screening rates of dyslipidemia in a pediatric primary
care setting. The objectives of this project are as follows:
1. Determine baseline dyslipidemia screening rates at the clinic prior to initiating
education.
2. Examine dyslipidemia screening rates after education has been given to staff at 1-,
4- and 6- weeks.
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3. Measure healthcare provider’s confidence and knowledge in both screening for
and managing dyslipidemia according to evidence-based guidelines.
Methods
Study Design
The design of this study was a descriptive pre and post design to evaluate if dyslipidemia
screening rates, knowledge, and self-efficacy of healthcare provider’s changed following an
education series at a general pediatric clinic. The rates of dyslipidemia screening were calculated
prior to providing provider education to see whether there was an improvement in screening
rates. Provider’s knowledge and confidence before the education series was also obtained after
receiving informed consent through a survey.
Setting
The setting of this study took place at a general pediatric clinic in Lexington, KY. The
mission of the organization is to provide leading-edge patient care while advancing professional
nursing and practice. This clinic serves a primary population of children between the ages of
birth to 18 years.
Sample/Participants
The sample of this study consisted of pediatric healthcare providers who worked at a
general pediatric clinic in Lexington, KY. The dates of the study were from September 10, 2018
through October 19, 2018. Healthcare providers were asked to take part in an anonymous survey
regarding their knowledge and confidence in dyslipidemia screening. The primary care office
consists of 21 physicians and 4 nurse practitioners. The total sample of the study involved 11
7

pediatric healthcare providers at a general pediatric clinic. The inclusion criteria were as follows:
any provider who performs a well-child exam for the pediatric population and is willing to
participate in the survey. The exclusion criteria were: 1) any provider who does not provide care
for the pediatric population and 2) any provider who is not willing to participate in the survey.
The secondary subjects of this study were the medical records of children between the
ages of 9 and 11 years who presented to a general pediatric clinic for an annual well-child exam.
Two hundred fifty-six medical records were extracted from Allscripts Electronic Health Record
(AEHR) between June 2018-August 2018 for all children between 9 and 11 years who presented
to the clinic for an annual well-child exam in order to determine pre-education screening rates.
Inclusion criteria were as follows: all children between the ages of 9 and 11 years who presented
to a general pediatric clinic for an annual well-child exam (refer to Table 1 for a comprehensive
list of ICD-10 and CPT codes used for inclusion criteria). Exclusion criteria consisted of: 1)
children younger than 9 years or older than 11 years and 2) all children, regardless of age, who
present to the clinic for an acute visit. Post-education screening rates were examined by
extracting medical records of children between 9 and 11 years who presented to the clinic for an
annual well-child exam from AEHR using the inclusion and exclusion criteria listed above
between the weeks of September 10, 2018 through October 19, 2018. 65 medical records were
pulled from AEHR for post-education screening rates.
Data Collection
Approval from the University of Kentucky Institutional Review Board (IRB) was
obtained in August 2018 prior to the collection of data. The patient medical records, healthcare
provider educational materials, and healthcare provider survey were the three tools utilized to
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assess whether dyslipidemia screening rates were affected at a general pediatric clinic throughout
the study. The educational materials provided were expected to change healthcare provider
behavior in terms of dyslipidemia screening in children between the ages of 9 and 11 years by
increasing awareness and updating them on current clinical practice guidelines endorsed by the
American Academy of Pediatrics and NHLBI (refer to Table 2 and Figure A). The anonymous
and voluntary surveys were used to assess whether healthcare providers felt both confident and
knowledgeable in screening, managing, and treating dyslipidemia in the pediatric primary care
population (refer to Table 3).
The primary investigator frequented the general pediatric clinic throughout the posteducation period between September 10, 2018 and October 19, 2018 and provided education and
surveys to healthcare providers who were present in the office at the time. There are 21
physicians and 4 nurse practitioners in the primary care clinic who were eligible to take this
survey. A total of 11 healthcare providers took part in both the education session and anonymous
survey. An e-mail reminder serving as an educational burst was sent out three weeks after the
project was started during the week of October 1, 2018, regardless of whether they participated
in the survey. This e-mail served as a reminder to screen for dyslipidemia (refer to Figure B).
Since the survey was completely anonymous, there was not a follow-up survey issued after the
educational series or completion of the project.
Data Analysis
The study utilized a descriptive pre and post design. Data Analysis Statistical Package for
the Social Sciences (SPSS) software was used in the analysis of data. Screening rates were
calculated into frequencies (%). The Chi-square test of association was used to compare
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dyslipidemia screening rates before and after the educational intervention was given in the
pediatric primary care clinic. The Chi-square test was also used after the educational burst e-mail
was sent to all healthcare providers three weeks after the start of the study. Each anonymous
survey response completed by healthcare providers was also calculated into frequencies (%).
Descriptive statistics, including means and standard deviations, were used to summarize
provider’s confidence and knowledge in dyslipidemia screening. SPSS software, version 24, with
an alpha level of 0.05 was used for statistical significance throughout analysis.
Results
Sample Characteristics
There were 256 medical records reviewed during the pre-education period between June
2018 and August 2018. During the six-week post-education period between September 10, 2018
and October 19, 2018, there were 65 medical records reviewed. The mean age of children
screened for dyslipidemia was 9.82 years. Of the 65 medical records reviewed during the posteducation period at a general pediatric clinic, 7 records were well-child visits for new patients
and 58 records were well-child visits for established patients.
Clinical Practice Guideline Adherence
Clinical practice guideline (CPG) adherence improved significantly after implementation
of the educational intervention. While adherence at this general pediatric clinic is still relatively
low compared to what the American Academy of Pediatrics (AAP) and NHLBI would like it to
be, it is significantly higher than the 2.5%-3.2% national average of adherence reported by the
Journal of American Medical Association (JAMA) in 2016 (Lozano et. al, 2016).
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There is a total of 25 advanced practice providers who perform well-child checks at a
general pediatric clinic. Eleven of the 25 providers (44%) participated in the educational session
and anonymous survey. Of the 256 medical records that were reviewed during the pre-education
period, 44 received dyslipidemia screening (17.2%). During the post-education period, 16 out of
the 65 medical records reviewed received dyslipidemia screening (24.6%, P=0.1701).
Dyslipidemia screening rates and adherence to the clinical practice guideline (CPG) improved
from 17.2% to 24.6%, an increase of 43%, at this general pediatric clinic after the educational
intervention was implemented. (Refer to Figure C and Table 4).
Adherence to clinical practice guidelines was also examined after an e-mail serving as an
educational burst was sent to providers at the clinic three weeks after the start of the study. All
healthcare providers, regardless of whether they received education, received this e-mail
reminding them of the evidence-based guidelines and the need to screen. Dyslipidemia screening
rates increased from 18.75% prior to the e-mail to 26.53% after the e-mail was sent (P=0.7409).
(Refer to Table 5).
Healthcare Provider Survey Data Analysis
Descriptive statistics, including means and standard deviations, were used to summarize
healthcare provider’s confidence and knowledge in dyslipidemia screening indicated by
anonymous survey results (Refer to Table 6 for a summary of survey results). The results yielded
that many healthcare providers do not feel confident in the evidence-based guidelines regarding
dyslipidemia screening and management in the pediatric primary care population. Furthermore,
many healthcare providers do not feel comfortable treating dyslipidemia in children between the
ages of 9 and 11 years.
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The educational intervention was beneficial in many different ways. As aforementioned,
there was a 43% increase in dyslipidemia screens after education was given in clinic. In addition,
81.8% of healthcare providers who participated in the survey strongly agreed that they felt more
confident in when and how to screen, diagnose, and manage dyslipidemia in children between
the ages of 9 and 11 years after they received education and were updated on the clinical practice
guidelines.
Discussion
The overall aim of this study was to assess whether healthcare provider education on
current evidence-based guidelines regarding dyslipidemia screening in children between the ages
of 9 and 11 years at annual well-child visits affected screening rates at the primary care clinic. As
childhood obesity rates continue to threaten to rise over the years, it is of increasing importance
that advanced practice providers are aware of when to screen children as well as how to interpret
and manage results.
Based on current screening rates, healthcare providers are not performing dyslipidemia
screening as often as recommended. The AAP 2013-2014 Periodic Survey of a national and
randomly selected sample of practicing AAP physicians found that 68% never/rarely/sometimes
screen healthy 9- to 11- year olds (De Ferranti, Rodday, et. al, 2017). This project identified that
current screening rates at this primary care setting prior to the intervention was similar to the
national rate. Overall, the study results and data analysis reveal that providing healthcare
providers with education increases screening rates.
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Limitations
There were a few limitations identified in this study that could be improved for future
studies down the road. The first limitation identified was the length of the study. Due to time
constraints with IRB approval and the end of the semester, the study was only conducted over a
6-week time frame. Perhaps if the length of the study was longer, results would be more
accurately depicted.
A second limitation had to do with the sample size of medical records reviewed. There
were significantly more medical records reviewed in the 3-month pre-education period than there
were in the 6-week post-education time frame. Since the pre-education period occurred over the
course of the summer, there was an influx of annual well-child exams before the start of the
school year. The post-education frame occurred once school was in session meaning that a many
children between the ages of 9 and 11 years had already received their annual exam for the year.
Perhaps if the pre- and post-education time periods were at the same time of the year, screening
results would be better analyzed.
To assess whether or not a child received dyslipidemia screening, information technology
conducted a chart analysis that assessed whether or not a specific box was checked in AEHR
under age-appropriate screenings. This box identified whether screening was either performed or
ordered at this visit. There is not a corresponding box that healthcare providers could check if a
child has already received dyslipidemia screening between the 9 to 11-year age range or at a
separate clinic. Therefore, the results could be falsely skewed.
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Lastly, healthcare provider and patient demographics were not reported in this study to
keep data confidential and private. While this safeguarded privacy, it also didn’t allow for
analysis of factors that may affect screening rates.
Recommendations for Future Studies
Recommendations for future studies include providing more continuing education to
healthcare providers in practice. While this study was specific to a pediatric primary care clinic,
family care clinics would also benefit greatly from education on current pediatric evidence-based
guidelines since family medicine providers also see pediatric patients. Incorporating screening
reminders within charting systems is a tool that needs to be implemented to increase screening
rates. This is a simple and cost-effective intervention that could drastically increase adherence to
clinical practice guidelines.
Another recommendation for future studies is to expand to multiple different ambulatory
clinic sites to increase sample size and draw results from a number of different settings. Lastly,
future studies should consider reasons why healthcare providers are not performing dyslipidemia
screening. From that information, researchers will be able to tell what is causing this wide gap in
practice and whether it’s due to a lack of knowledge, cost standpoint, parental refusal, or
insurance coverage.
Conclusion
The overall goal of my project was to increase screening rates of dyslipidemia in all
children between the ages of 9 and 11 years at a primary care pediatric clinic. Throughout the
course of the six-week study, screening rates improved by 43%. Not only that, but 81.8% of
healthcare providers felt that they benefited from the educational intervention and now feel more
14

confident and knowledgeable in screening, diagnosing, and managing dyslipidemia in the
primary care setting. The educational intervention implemented in this study promoted evidencebased care and provided patients with the best quality preventive care.
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Table 1. Inclusion Criteria List of Annual Well-Child Exam ICD-10 and CPT Codes
ICD-10 Codes

Diagnosis Definition

CPT Code

Diagnosis Definition

Z00.121

New and/or
Established Patient
Well-Child Exam

99383

New Patient WellChild Exam Late
Childhood (Age 511 years)

Z00.129

New and/or
Established Patient
Well-Child Exam

99393

Established Patient
Well-Child Exam
Late Childhood
(Age 5-11 years)
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Table 2. Definition of Lipid Levels in Children from the 2011 Expert Panel Integrated
Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents

Acceptable

Borderline

mg/dL (mmol/L)

mg/dL (mmol/L)

Category

HighΔ

TC

<170 (4.4)

170 to 199 (4.4 to 5.2)

≥200 (5.2)

LDL-C

<110 (2.8)

110 to 129 (2.8 to 3.3)

≥130 (3.4)

Non-HDL-C

<120 (3.1)

120 to 144 (3.1 to 3.7)

≥145 (3.8)

ApoB

<90 (2.3)

90 to 109 (2.3 to 2.8)

≥110 (2.8)

• 0 to 9 years

<75 (0.8)

75 to 99 (0.8 to 1.1)

≥100 (1.1)

• 10 to 19 years

<90 (1 mmol/L)

90 to 129 (1 to 1.5)

≥130 (1.5)

TG

Category

Acceptable

Borderline

LowΔ

HDL-C

>45 (1.2)

40 to 45 (1 to 1.2)

<40 (1)

ApoA-1

>120 (3.1)

115 to 120 (3 to 3.1)

<115 (3)

TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein; ApoB: apolipoprotein B;
ApoA-1: apolipoprotein A-1; TG: triglycerides.
Table adapted from UpToDate retrieved at
https://www.uptodate.com/contents/image?imageKey=PEDS%2F68183&topicKey=PEDS%2F16972&search=dyslipidemia%20
screening%20in%20children&rank=1~150&source=see_link
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Table 3. Provider Confidence in Screening for and Treating Dyslipidemia in 9- to 11-yearolds at a Pediatric Primary Care Clinic
Strongly Disagree

Disagree

All children
between the ages
of 9-11 years who
present for an
annual exam
should be screened
for dyslipidemia.
I use the evidencebased guidelines
regarding
dyslipidemia
screening and
management in the
pediatric primary
care population
when performing
well-child checks.

I know when and
how to screen for
dyslipidemia in
children between
9-11 years in the
pediatric primary
care setting.
I know how to
diagnose
dyslipidemia in
children between
9-11 years in the
pediatric primary
care setting.
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Agree

Strongly Agree

I know how to
manage
dyslipidemia in
children between
the ages of 9-11
years in the
pediatric primary
care setting.
The education
received today was
helpful in regards
to knowing when
and how to screen,
diagnose, and
manage
dyslipidemia in
children between
the ages of 9 and
11 years.
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Table 4. Percentage of Dyslipidemia Screenings Pre- and Post- Education
Pre- and Post- Education
Time

Screened
0

Pre

1 Total

212

44

82.81

17.19

49

16

75.38

24.62

261

60

Post

Total
Statistic
Chi-Square

DF Value

256

65

321
Prob

1 1.8819 0.1701
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Table 5. Percentage of Dyslipidemia Screenings Pre- and Post- Educational Burst E-mail
Educational Burst E-Mail
Time

Screened
0

1

2

Total

1 Total

13

3

81.25

18.75

36

13

73.47

26.53

49

16

16

49

65

Fisher’s Exact Test
Table Probability (P) 0.2269
Two-sided Pr <= P

21

0.7409

Table 6. Summary of Healthcare Provider’s Confidence and Knowledge in Screening and
Managing Dyslipidemia (N = 11)
Question

Mean (SD)

All children between 9-11 years who present for
an annual well-child exam should be screened for
dyslipidemia

3.6 (0.5)

I use the evidence-based guidelines regarding
dyslipidemia screening when I perform well-child
checks

3 (0.8)

I know when and how to screen for dyslipidemia

3.5 (0.7)

I know how to diagnose dyslipidemia

3.2 (0.8)

I know how to manage dyslipidemia

2.7 (0.8)

The education received was helpful in regards to
knowing when and how to screen, diagnose, and
manage dyslipidemia in children between the ages
of 9 and 11 years

3.8 (0.4)
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Figure A: Educational Handout for Healthcare Providers at a General Pediatric
Clinic
Title of Project
Dyslipidemia Screening in Children between 9 and 11 Years in a Pediatric Primary Care Clinic:
An Evidence-Based Approach.
Purpose
The purpose of this project is to examine the outcome of healthcare provider education on the
incidence of dyslipidemia screening in a pediatric primary care clinic. The rates of dyslipidemia
screening will be examined prior to providing education as well as afterwards through a
descriptive pre and post design. The overall goal of my project is to increase screening rates of
dyslipidemia at a general pediatric clinic.
Objectives
#1: Determine baseline dyslipidemia screening rates at the clinic prior to initiating education.
#2: Examine dyslipidemia screening rates after education has been given to staff at 1-, 4- and 6weeks.
#3: Measure healthcare provider’s confidence and knowledge in both screening for and
managing dyslipidemia according to evidence-based guidelines.
Fast Facts
 Dyslipidemia is a known risk factor for CVD that manifests during childhood and
adolescence
 Dyslipidemia in children is characterized by disorders of lipoprotein metabolism that
result in the following abnormalities: high total cholesterol, high low-density lipoprotein
cholesterol, high triglycerides, and low high-density lipoprotein cholesterol.
 20% of children in the United States between the ages of 6 & 19 years have adverse
levels of one or more lipid value and often exhibit no signs or symptoms
 It is estimated that 50% of children with abnormal serum lipoprotein values will
continue to have elevated lipid levels into adulthood
 Approximately 100,000 children under the age of 17 and 400,000 adolescents between
the ages of 17 & 21 would qualify for statin therapy in the United States based on the
current NHBLI and AAP recommendations
 An analysis of National Health and Nutrition Examination Survey (NHAMES), it was
found that 14% of youths who were normal weight, 22% of youths who were
overweight, and 43% of youths who were obese had adverse lipid levels
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AAP Practice Recommendation for Pediatric Primary Care
The American Academy of Pediatrics (AAP) in conjunction with the NHLBI Expert Panel on
Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and
Adolescents endorse that all children between the ages of 9 and 11 years undergo dyslipidemia
screening before the onset of puberty
Why Screen?
Through early identification of dyslipidemia, a child’s lipid profile can be improved through
lifestyle modifications or medication which reduces their risk of developing premature
atherosclerosis and CVD in the future
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Figure B: Educational burst sent to healthcare providers at a General Pediatric
Clinic
To Providers at a general pediatric clinic,
My name is Meredith Toms and I am a Graduate DNP Student at the University of
Kentucky. As many of you may know, I am conducting my final DNP project that examines
dyslipidemia screening rates in children between the ages of 9-11 years following an education
session that has previously been given. This is a friendly reminder to be screening all children
between the ages of 9 and 11 years who present to the clinic for a well-child check.
The American Academy of Pediatrics (AAP) in conjunction with the NHLBI Expert
Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and
Adolescents endorse that all children between the ages of 9 and 11 years undergo dyslipidemia
screening before the onset of puberty. Through early identification of dyslipidemia, a child’s
lipid profile can be improved through lifestyle modifications or medication which reduces their
risk of developing premature atherosclerosis and CVD in the future.
Thank you for taking the time to read this and for taking such good care of all kids seen
at this general pediatric clinic! If you have questions about the study, please feel free to ask; my
contact information is given below.
Sincerely,
Meredith Toms, RN, BSN, Graduate DNP Student
University of Kentucky
513-600-6401
mrco225@uky.edu
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Figure C: Graph of Dyslipidemia Screening Pre- and Post- Healthcare Provider
Education
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